ORDERSWhat I like about Mir is that they have a product to sell. Financials were bad, but I think the product is good enough to turn the tide. Other biotechs go up on positive phase 2 results and then fail with their products. Allot of money has been wasted here, but Morningside and others are interested in Mir's products. It's only a matter of time that Mir Will be put on the map. Similar U.S. companies are doing very well. I think Mir could take a piece of the pie without diluting the rest of the market.